Epidemiological and genetic insights into the co-occurrence of cutaneous melanoma and hematologic malignancies: A meta-analytic review.

Leuk Res

School of Medicine and Dentistry, Griffith University, Gold Coast Campus, Gold Coast 4222, Australia. Electronic address:

Published: December 2024

AI Article Synopsis

  • The study explores the growing number of cancer survivors and investigates the connection between cutaneous melanoma (CM) and hematologic malignancies (HM), examining how genetic, biological, and environmental factors influence this association.!* -
  • A literature review and meta-analysis were conducted, analyzing data from ten studies on HM in CM patients and eleven studies on CM in HM patients, revealing significant incidence ratios for both cancers appearing after one another.!* -
  • The findings confirm a notable link between CM and HM, primarily driven by genetic factors (like specific gene mutations) and environmental risks (such as UV exposure and weakened immune systems).!*

Article Abstract

Background: The number of cancer survivors has been increasing in recent years due to advancements in early diagnosis and prolonged survival. Existing literature suggests a connection between cutaneous melanoma (CM) and hematologic malignancies (HM).

Aim: This study aims to examine epidemiological research on the link between CM and HM and explore genetic, biological, and environmental factors contributing to this association.

Methodology: A literature review and meta-analysis were performed to evaluate the risk of CM following HM and vice versa. Data from included studies, which reported standardized incidence ratios (SIR) or hazard ratios (HR) with 95 % confidence intervals (CI), were pooled using a random effects model. Heterogeneity among studies was assessed using I² and Cochrane Q test statistics. The incidence data were pooled using a random effects model. This review is registered on PROSPERO (CRD42022359887).

Results: Ten studies focused on HM diagnosis in CM patients, comprising a combined cohort of 189,094 individuals and 11 focused on CM diagnosis in HM patients in a cohort of 306,967 individuals. The SIR for HM after CM ranged from 1.25 to 3.12, while the SIR for CM after HM ranged from 0.83 to 4.12. The pooled proportion of HM in CM patients was 62.4 %, and the proportion of CM in HM patients was 19.6 %. Statistical heterogeneity was high, with I² values of 99.19 % and 89.15 %, respectively.

Conclusion: This review confirms an association between CM and HM within the same patient. The link is primarily attributed to genetic factors involving BRAF-V600K, tyrosine kinase pathway genes, CDKN2A (P16), and BCL-2. Additionally, risk factors such as ultraviolet radiation and compromised immune function are associated with the incidence of these cancers.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2024.107610DOI Listing

Publication Analysis

Top Keywords

cutaneous melanoma
8
melanoma hematologic
8
hematologic malignancies
8
pooled random
8
random effects
8
effects model
8
focused diagnosis
8
diagnosis patients
8
sir ranged
8
proportion patients
8

Similar Publications

Purpose: In CheckMate 204, nivolumab + ipilimumab showed high intracranial (IC) objective response rates (icORRs) in patients with melanoma brain metastases (MBMs). Using icORR as a surrogate for overall survival (OS) has prompted use of alternate response criteria. To set the stage for harmonized MBM trials, the aim of this exploratory analysis was to determine icORR using several response criteria and examine correlations of response with survival.

View Article and Find Full Text PDF

Functional differences between rodent and human PD-1 linked to evolutionary divergence.

Sci Immunol

January 2025

Department of Cell and Developmental Biology, School of Biological Sciences, University of California San Diego, La Jolla, CA 92093, USA.

Mechanistic understanding of the inhibitory immunoreceptor PD-1 is largely based on mouse models, but human and mouse PD-1 share only 59.6% amino acid identity. Here, we found that human PD-1 is more inhibitory than mouse PD-1, owing to stronger interactions with the ligands PD-L1 and PD-L2 and more efficient recruitment of the effector phosphatase Shp2.

View Article and Find Full Text PDF

Mitochondrial DNA (mtDNA) is highly polymorphic, and host mtDNA variation has been associated with altered cancer severity. To determine the basis of this mtDNA-cancer association, we analyzed conplastic mice with the C57BL/6J (B6) nucleus but two naturally occurring mtDNA lineages, and , where mitochondria generate more oxidative phosphorylation (OXPHOS)-derived reactive oxygen species (mROS). In a cardiac transplant model, Foxp3+ T regulatory (Treg) cells supported long-term allograft survival, whereas Treg cells failed to suppress host T effector (Teff) cells, leading to acute rejection.

View Article and Find Full Text PDF

The Role of Radiotherapy in the Management of Melanoma Brain Metastases: An Overview.

Curr Treat Options Oncol

January 2025

Ella Lemelbaum Institute for Immuno Oncology, Chaim Sheba Medical Center, 6997801, Tel Aviv, Israel.

Clinical management of melanoma brain metastases is complex and requires multidisciplinary approach. With close collaboration between neurosurgeons, radiation oncologists and medical oncologists, melanoma patients with brain are offered different treatment modalities: surgery, radiation therapy, systemic therapy or combined treatments. Radiation therapy (whole brain radiotherapy- WBRT and stereotactic radiosurgery- SRS) is an integral part of treating melanoma brain metastases.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!